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The Accuracy of Clinical Staging of Stage
I-IIIa Non-Small Cell Lung Cancer
An Analysis Based on Individual Participant Data
Neal Navani, MD, PhD; David J. Fisher, MSc; Jayne F. Tierney, PhD; Richard J. Stephens;
Sarah Burdett, MSc; on behalf of the NSCLC Meta-analysis Collaborative Group*
BACKGROUND: Clinical staging of non-small cell lung cancer (NSCLC) helps determine the
prognosis and treatment of patients; few data exist on the accuracy of clinical staging and the
impact on treatment and survival of patients. We assessed whether participant or trial
characteristics were associated with clinical staging accuracy as well as impact on survival.
METHODS: We used individual participant data from randomized controlled trials (RCTs),
supplied for a meta-analysis of preoperative chemotherapy ( radiotherapy) vs surgery alone
( radiotherapy) in NSCLC. We assessed agreement between clinical TNM (cTNM) stage at
randomization and pathologic TNM (pTNM) stage, for participants in the control group.
RESULTS: Results are based on 698 patients who received surgery alone ( radiotherapy) with
data for cTNM and pTNM stage. Forty-six percent of cases were cTNM stage I, 23% were
cTNM stage II, and 31% were cTNM stage IIIa. cTNM stage disagreed with pTNM stage in
48% of cases, with 34% clinically understaged and 14% clinically overstaged. Agreement was
not associated with age (P ¼ .12), sex (P ¼ .62), histology (P ¼ .82), staging method
(P ¼ .32), or year of randomization (P ¼ .98). Poorer survival in understaged patients was
explained by the underlying pTNM stage. Clinical staging failed to detect T4 disease in
10% of cases and misclassiﬁed nodal disease in 38%.
CONCLUSIONS: This study demonstrates suboptimal agreement between clinical and patho-
logic staging. Discrepancies between clinical and pathologic T and N staging could have led
to different treatment decisions in 10% and 38% of cases, respectively. There is therefore a
need for further research into improving staging accuracy for patients with stage I-IIIa
NSCLC. CHEST 2019; 155(3):502-509
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The clinical staging of non-small cell lung cancer (NSCLC)
is of paramount importance in determining a patient’s
prognosis, guiding treatment decisions, and deﬁning
clinical trial eligibility, as well as allowing comparison
between clinical trials. Incorrect staging of NSCLC may
result in inaccurate prognostic information for patients
and errors in patient treatment. After extrathoracic
metastases have been excluded, tumor and nodal staging
are critical in making treatment decisions, as patients with
N0 and N1 involvement are generally candidates for
surgery. Patients with ipsilateral mediastinal disease (N2)
are a heterogeneous group and may be offered
chemoradiation therapy or surgery (with preoperative or
postoperative chemotherapy). Patients with contralateral
(N3) mediastinal (or supraclavicular) nodal disease are
offered chemoradiation therapy or palliative treatment
options. Therefore, clinical understaging, that is, staging
thatmisses mediastinal metastases ormediastinal invasion
of the primary lesion, may risk the patient undergoing
radical treatment of the primary lesion for no beneﬁt.
Conversely, incorrect clinical overstaging of mediastinal
disease may result in surgery being denied to an otherwise
operable patient. The current guidance from the Union for
International Cancer Control1 suggests that when there is
doubt about stage, the less advanced, or lower category
should be chosen.
The emergence of techniques such as stereotactic body
radiotherapy2 (SABR) and radiofrequency ablation3 to
treat early-stage NSCLC in medically inoperable patients
has further highlighted the importance of accurate
clinical staging. Applying local nonsurgical treatments
without the beneﬁt of systematic lymph node dissection
runs the risk of being futile if there is clinical
understaging with unrecognized mediastinal or systemic
disease.
Although the importance of accurate clinical staging is
clear and the performance characteristics of individual
tests in lung cancer staging are known, fewer data exist
on the accuracy of clinical staging of NSCLC and how
this relates to the staging techniques employed. Three
studies that have been reported all show high levels of
inaccurate clinical staging; however, none have
demonstrated the impact of erroneous staging on
clinical outcome. A prospective study of 383 patients
with potentially resectable NSCLC demonstrated that
clinically unsuspected N2 disease was found in 14% of
patients. Despite routine use of positron emission
tomography-computed tomography (PET-CT)
scanning,4 a post-hoc analysis of 67 patients from the
control arm of the Medical Research Council LU225 trial
of preoperative chemotherapy suggested that nodal
staging was inaccurate in 25% (95% CI, 15%-36%) of
patients who underwent PET-CT scanning and
mediastinoscopy.6 A study comparing clinical and
pathologic TNM data, collected for 2,336 patients
included in the Dutch Lung Surgery Audit,7 showed that
only 54% of patients were clinically staged accurately,
and no comment could be made on whether this
impacted on patient survival outcomes. Thus, to
investigate further, we used individual participant data
(IPD) from trials supplied for a systematic review and
meta-analysis of preoperative chemotherapy in non-
small cell lung cancer to assess the accuracy of clinical
staging, factors that may affect inaccuracy, and how
inaccuracy might impact on treatment decisions and
survival.
Methods
To be eligible for inclusion in the original IPD meta-analysis,8 trials
should have randomized patients with NSCLC to preoperative
chemotherapy followed by surgery ( postoperative radiotherapy)
vs surgery ( postoperative radiotherapy). Full details of the
methods are presented elsewhere.8 IPD were collected for 15 eligible
randomized controlled trials and included 2,385 patients with non-
small cell lung cancer.8 However, only data from patients from the
control arm in these trials were used in this analysis, to ensure that
any difference between clinical and pathologic staging could not
have been inﬂuenced by preoperative chemotherapy. Included
randomized controlled trials (RCTs) used different editions of TNM
staging, and these changes over time were taken into account
(e-Table 1).
Data on age, sex, clinical staging techniques, clinical TNM stage, extent
of resection, pathologic TNM stage, histology, performance status,
treatment group and dates of randomization, last follow-up, and
death were collected. We approached study investigators for
permission to use these data for these analyses and for clariﬁcation
where staging methods were unclear in the original trial protocol or
manuscript.
Statistical Analysis
To assess agreement between clinical TNM stage (cTNM) and
pathologic TNM stage (pTNM), a simple percentage agreement was
calculated. Agreement between clinical and pathologic stage was also
calculated using a weighted Cohen’s k, which takes into account
both agreement by chance and the degree of disagreement. k
statistics were categorized, as < 66% ¼ low agreement, $ 66% ¼
fair agreement, and $ 90% ¼ good agreement.9,10
To assess whether or not patient and trial characteristics might be
associated with any cTNM staging inaccuracy age, sex, histology,
year of randomization, and staging method were included in a
multivariate logistic regression model. Histology was classiﬁed
into adenocarcinoma, squamous, and other/unknown. Staging
methods were classiﬁed as CT scan with or without a chest
radiograph or CT scan plus any other staging method, as there
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were insufﬁcient data to do this in more detail. Staging method
correlated strongly with year of randomization, so we included
only the former in our primary analysis. However, a sensitivity
analysis was also performed, where staging method was replaced
with year of randomization. We generated Kaplan-Meier curves
for overall survival based on patients who were clinically
understaged, clinically overstaged, and for those whose cTNM
and pTNM agreed, and compared these using a log-rank test,
stratiﬁed by trial and subsequently also pathologic stage. The
accuracy of clinical T stage and nodal status were considered
separately to help pinpoint which disagreements could have
inﬂuenced treatment decisions.
Results
Fifteen RCTs were included in the original IPD
systematic review and meta-analysis of preoperative
chemotherapy followed by surgery vs surgery alone.
Nine trials5,11-18 (randomizing 1,586 patients in total)
included data on both cTNM and pTNM stage,
providing 698 control-arm patients for analysis
(Table 1). These RCTs accrued patients between 1987
and 2005.
Clinical staging protocols varied among the trials
(Table 1). One trial11 (which recruited patients between
1987 and 1993) used chest radiography and
mediastinoscopy only. More recent trials used CT scans
and PET-CT imaging, but no trial utilized PET-CT
scanning routinely, such that only 67 patients included
in the analysis underwent PET-CT imaging. There was
also variation among trials in the surgical methods used
(Table 1).
Of the 698 patients included, 318 (46%) were cTNM
stage I (83% of which were Ia), 160 (23%) were cTNM
stage II (91% of which were IIa), and 218 (31%) were
cTNM stage IIIa (Table 2). Only two patients were
classed as cTNM stage IIIB, and were therefore not
included in the regression or survival analyses. A more
detailed breakdown is given in e-Figure 1.
Agreement between cTNM and pTNM staging was low
(52%; weighted Cohen’s k ¼ 0.35; 95% CI, 0.30-0.40)
(Table 2). In 34% of cases, patients were clinically
understaged, and in 14% of cases, patients were clinically
overstaged (Table 2). In the main regression analysis, age
(P ¼ .12), sex (P ¼ .62), histology (P ¼ .82), and the
staging method (P ¼ .32) were not signiﬁcantly
associated with the accuracy of cTNM staging, and in a
sensitivity analysis there was no association with year of
randomization (P ¼ .98; e-Table 2).
Survival varied with the accuracy of cTNM staging. In
particular, patients who were clinically understaged
appeared to have poorer survival than those who were
clinically overstaged or those for whom cTNM and
pTNM staging agreed (log-rank test stratiﬁed by trial
P < .0001) (Fig 1). However, this is driven by the
underlying pTNM stage (log-rank test stratiﬁed by trial
and pathologic stage P ¼ .54), which is more clearly
illustrated in Figure 2. In particular, 44% of patients
classed as cTNM stage I were pTNM stage II-IV, and
33% of patients classed as cTNM stage II were pTNM
stage III-IV, explaining their lower survival (Fig 2).
Agreement was low between clinical and pathologic T
stage (65%; weighted Cohen’s k ¼ 0.33; 95% CI, 0.27-
0.39) (Table 3) and N stage (62%, weighted Cohen’s k ¼
0.42; 95% CI, 0.37-0.48) (Table 4). Speciﬁcally, clinical
staging failed to detect T4 disease in 10% of patients
(Table 3), and nodal disease in 19% of patients. In
addition, 12% were judged erroneously to have node-
positive disease (Table 4).
Discussion
Results Summary
We found that cTNM stage disagreed with pTNM stage
in about one-half of patients, and was not clearly
associated with age, sex, histology, the staging method
used, or year of randomization. The discrepancies
between clinical and pathologic T staging and N staging
could have led to different treatment decisions in
10% and 38% of cases, respectively.
Strengths
To our knowledge, this is the ﬁrst time IPD from major
RCTs have been combined to assess the accuracy of
staging in stage I-III NSCLC. While the randomized
controlled trials included did not intend to evaluate
staging, with the agreement of those who provided the
data, this novel methodology provided us with a valuable
opportunity to investigate more reliably the accuracy of
clinical TNM staging. We could take advantage of per-
protocol clinical staging and surgery and rigorous
documentation of clinical and pathologic TNM stage for
each patient. Also, data from randomized trials are less
susceptible to the selection biases that can affect cohort
studies.19,20 Using IPD has enabled us to restrict the
analysis to the control arms of these trials, thus avoiding
confounding by treatment received and, in particular,
potential downstaging from use of preoperative
chemotherapy.
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TABLE 1 ] Characteristics of Included Trials
Trial
Total Patients
Randomized
Patients
Randomized to
Control Arm
Patients Who
Provided Clinical
and Pathologic
Data
Accrual
Period
Staging
System
(TNM)a Staging Method Surgical Protocol
M.D. Anderson
(USA); Roth
et al11/1994
60 32 32 1987-1993 4 Chest radiography One or more positive nodal stations
allowed. Patients with left lung tumors
and paratracheal lymph node
metastases excluded
MIP-91 (France);
Depierre et al12/
2002 (12, 29)
355 176 170 1991-1997 4 Chest radiography,
CT imaging
Mediastinal node dissection and node
sampling were left to the discretion of
the surgeon
Netherlands;
Splinter et al13/
2000
79 40 37 1991-1999 4 CT imaging and
mediastinoscopy
Mediastinal lymph node exploration was
encouraged: for right-sided lesions, this
included 2R, 4R, 7, 8, 9. For left-sided
lesions, this included 4L, 5, 6, 7, 8, 9
JCOG 9209
(Japan); Nagai
et al14/2003
62 31 31 1993-1998 4 CT imaging Surgery was either lobectomy,
bilobectomy, or pneumonectomy along
with systematic mediastinal lymph
node dissection
Finland; Mattson
et al15/2003
62 32 23 1995-1999 4 CT imaging “Local surgery”
MRC LU22 (UK);
Gilligan et al5/
2007
519 261 194 1997-2005 5/6 Bronchoscopy,
mediastinoscopy,
and CT imaging,
PET
At cervical mediastinoscopy, the following
lymph node stations will, wherever
possible, be sampled: 2R, 2L, 4R, 4L, 7
SWOG S9900
(USA); Pisters
et al16/2010
354 174 170 1999-2004 5/6 Chest radiography
and CT imaging
All accessible hilar (level 10) lymph nodes
must be dissected .A complete
mediastinal lymph node sampling
should be performed.for right-sided
lesions, this includes 2R, 4R, 7, 8, and
9. For left-sided lesions, this includes
4L, 5, 6, 7, 8, and 9
China; Wu et al17/
2002
55 23 20 1999-2004 5/6 Chest radiography,
CT imaging,
bronchoscopy and
abdominal
ultrasound
Surgery consisted of radical lung
resection and systematic mediastinal
lymph node dissection
China; Yang
et al18/2005
40 21 21 1999-2004 5/6 Chest radiography,
CT imaging,
bronchoscopy and
abdominal
ultrasound
Lobectomy or pneumonectomy with
systematic lymph node dissection
aFor details of TNM staging systems, see e-Figure.
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For the ﬁrst time, to our knowledge, this study also
demonstrates the impact of the inaccuracy of clinical
staging on patient survival outcomes. Importantly, the
impact of staging accuracy on clinical decision making is
also demonstrated using unselected data. The poorer
survival seen in clinically understaged patients was
explained by the underlying pTNM stage.
Limitations
Over time the trials included here used increasingly
sophisticated staging methods, but surprisingly, a
signiﬁcant improvement in accuracy was not seen.
However, many of the staging methods utilized in the
included trials may now be considered suboptimal.21
Earlier studies employed CT scanning and
mediastinoscopy while the most recent trial used
additional PET-CT imaging, but none used
endosonography. Despite this, our staging accuracy
results are remarkably similar to those from the audit of
the quality of staging in Dutch patients,7 which included
routine use of PET-CT imaging and endosonography
and included patients from January 2013 to December
2014. Indeed, of the patients included in our analysis
that did undergo PET-CT imaging, one-quarter of
patients were still understaged and this is discussed
elsewhere.6 While PET-CT imaging or endosonography
was not routinely utilized in the trials included in this
meta-analysis, this practice reﬂects current American
College of Chest Physicians guidance22 for patients with
stage IA disease, which does not recommend the use of
PET imaging or endosonography. Although it is difﬁcult
to generalize, assuming the trial population reﬂects
routine practice, the data here suggest that 44% of
patients with clinical stage I disease might have more
advanced disease diagnosed postoperatively. A further
limitation is that intraoperative pathologic staging
protocols may have varied and are unlikely to be as
comprehensive as currently recommended.23 However,
incomplete pathologic staging would only serve to
reduce the extent of nodal staging inaccuracy.
Context
The advent of stereotactic radiotherapy and
radiofrequency ablation for the treatment of early-stage
NSCLC has highlighted the importance of accurate
nodal staging. These newer techniques are used for the
treatment of early-stage lung cancer but, in contrast to
surgery, do not provide pathologic staging information.
In a study of relapse of NSCLC following stereotactic
radiotherapy or surgery, there were twice as many
recurrences in local lymph nodes in patients undergoing
stereotactic radiotherapy compared with surgery,24
emphasizing the importance of accurate nodal staging
prior to SABR.
When surgery is undertaken and pathologic staging is
available, prior invasive mediastinal sampling may take
on less signiﬁcance if we assume that surgery followed
by adjuvant chemotherapy is at least as effective as
TABLE 2 ] Agreement Between Clinical and Pathologic TNM Stage Data
TNM Stage
TNM Stage
TotalpI pII pIIIa pIIIb pIV
cI 177 (25.4%) 72 (10.3%)a 44 (6.3%)a 22 (3.2%)a 3 (0.4%)a 318 (45.6%)
cII 40 (5.7%)b 67 (9.6%) 32 (4.6%)a 16 (2.3%)a 5 (0.7%)a 160 (22.9%)
cIIIa 32 (4.6%)b 28 (4.0%)b 116 (16.6%) 30 (4.3%)a 12 (1.7%)a 218 (31.2%)
cIIIb 0b 0b 0b 2 (0.3%) 0a 2 (0.3%)
cIV 0b 0b 0b 0b 0 0
Total 249 (35.7%) 167 (23.9%) 192 (27.5%) 70 (10.0%) 20 (2.9%) 698 (100%)
aClinically understaged.
bClinically overstaged.
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Figure 1 – Kaplan-Meier curves for overall survival for all trial data
combined, by agreement of clinical TNM staging with pathologic TNM
staging.
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chemoradiation. When considering stage II and III
disease, inaccurate clinical staging may reduce the
efﬁcacy of surgery by failing to detect multistation N2 or
N3 disease. For patients undergoing radical
radiotherapy, imprecise clinical staging can result in an
incorrect radiation ﬁeld.
The most likely explanation for the low level of accuracy
of clinical staging for patients with operable NSCLC is
the sensitivity of the diagnostic tools employed. Patients
being considered for treatment with curative intent
typically undergo CT and PET-CT imaging as well as
mediastinal sampling when required. Using a 10-mm
short-axis cutoff for signiﬁcance of mediastinal nodes,
the sensitivity of CT scanning in detecting mediastinal
metastases is 55%.22 PET-CT imaging has a sensitivity
of 77% to 81%25 and may vary according to brand of
scanner and histology. In a systematic pooled analysis of
9,267 patients, mediastinoscopy had a sensitivity of
78%.22 Overstaging may occur with PET-CT imaging
unless current guidelines22 are adhered to and PET-
positive ﬁndings are clariﬁed by invasive sampling.
More recently the introduction of endobronchial and
endoscopic ultrasound has improved the clinical staging
of patients with NSCLC, resulting in a reduction in
futile surgery26,27 and potentially increased survival28
Clinical understaging
Agreement
Clinical overstaging
44%
56%
0%
33%
42%
25%
19%
Stage I Stage II Stage III
53%
28%
0.00
0 1 2
Stage I
318 (46%)
Pathological stage II-IV
3 4 5
0.25
0.50
0.75
1.00
S
u
rv
iv
a
l
Analysis Time (y)
Stage II
160 (23%)
Total N = 696
Clinical TNM stage
Pathological stage III-IV
Pathological stage I
0 1 2 3 4 5
Analysis Time (y)
Stage III
218 (31%)
Pathological stage IV
Pathological stage I-II
0 1 2 3 4 5
Analysis Time (y)
Figure 2 – Kaplan-Meier curves for overall survival in clinically staged I, II, and III patients, by agreement of clinical TNM staging with pathologic
TNM staging.
TABLE 3 ] Agreement Between Clinical and Pathologic T Stage Data
T Stage
T Stage
TotalpT1 pT2 pT3 pT4
cT1 34 (4.9%) 16 (2.3%)a 3 (0.4%)a 7 (1.0%)a 60 (8.6%)
cT2 35 (5.0%)b 360 (51.6%) 69 (9.9%)a 40 (5.7%)a 504 (72.2%)
cT3 7 (1.0%)b 42 (6.0%)b 60 (8.6%) 23 (3.3%)a 132 (18.9%)
cT4 0b 0b 0b 2 (0.3%) 2 (0.3%)
Total 76 (10.9%) 418 (59.9%) 132 (18.9%) 72 (10.3%) 698 (100%)
aClinically understaged.
bClinically overstaged.
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when employed routinely for patients with stage I-III
disease.
Implications
These ﬁndings have implications for the care of patients
with NSCLC, as well as appropriate selection of suitable
patients for inclusion in clinical trials. Understaging the
T stage may mean that the patient undergoes surgery
without the surgeon knowing the full extent of the
primary disease, which may result in an incomplete
resection. Ten percent of patients in our analysis were
found to have previously unexpected T4 disease.
Erroneous nodal staging in patients without metastatic
disease can similarly result in inappropriate treatment
decisions, which can signiﬁcantly impact on patient
outcomes. Patients with nodal disease undetected by
clinical staging methods may undergo futile surgery (or
SABR) whereas chemoradiotherapy may have been the
preferred initial treatment of clinicians and patients with
full knowledge of nodal involvement. Conversely, if
clinical staging overestimates the extent of nodal disease
(114 patients [15%] in this meta-analysis), then this may
mean patients are denied potentially curative surgery.
The data for this analysis were obtained from patients in
controlled clinical trials, generally from centers with
lung cancer expertise. Therefore, clinical staging
accuracy in the wider population could well be worse.
Conclusions
The results of this analysis highlight some ﬂaws in the
clinical care of patients with NSCLC and emphasize the
need for further research into techniques for improving
staging accuracy for patients with stage I-III NSCLC.
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